IL200619A - Solid oral dosage forms containing 1 - [6 - [03 - cyclobutyl - 2, 3, 4, 5 - tetrahydro - 1 h - 3 benzazepine - 7 - yl) and xi] - 3 - pyridinyl} - 2 - pyrrolidinone or its appropriate parametabic salt , And methods for preparing them - Google Patents

Solid oral dosage forms containing 1 - [6 - [03 - cyclobutyl - 2, 3, 4, 5 - tetrahydro - 1 h - 3 benzazepine - 7 - yl) and xi] - 3 - pyridinyl} - 2 - pyrrolidinone or its appropriate parametabic salt , And methods for preparing them

Info

Publication number
IL200619A
IL200619A IL200619A IL20061909A IL200619A IL 200619 A IL200619 A IL 200619A IL 200619 A IL200619 A IL 200619A IL 20061909 A IL20061909 A IL 20061909A IL 200619 A IL200619 A IL 200619A
Authority
IL
Israel
Prior art keywords
dosage form
pyrrolidinone
tetrahydro
benzazepin
oxy
Prior art date
Application number
IL200619A
Other languages
English (en)
Hebrew (he)
Other versions
IL200619A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL200619A0 publication Critical patent/IL200619A0/en
Publication of IL200619A publication Critical patent/IL200619A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
IL200619A 2007-03-01 2009-08-27 Solid oral dosage forms containing 1 - [6 - [03 - cyclobutyl - 2, 3, 4, 5 - tetrahydro - 1 h - 3 benzazepine - 7 - yl) and xi] - 3 - pyridinyl} - 2 - pyrrolidinone or its appropriate parametabic salt , And methods for preparing them IL200619A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89226707P 2007-03-01 2007-03-01
PCT/EP2008/052430 WO2008104590A2 (en) 2007-03-01 2008-02-28 Novel dosage form

Publications (2)

Publication Number Publication Date
IL200619A0 IL200619A0 (en) 2010-05-17
IL200619A true IL200619A (en) 2014-09-30

Family

ID=39248198

Family Applications (1)

Application Number Title Priority Date Filing Date
IL200619A IL200619A (en) 2007-03-01 2009-08-27 Solid oral dosage forms containing 1 - [6 - [03 - cyclobutyl - 2, 3, 4, 5 - tetrahydro - 1 h - 3 benzazepine - 7 - yl) and xi] - 3 - pyridinyl} - 2 - pyrrolidinone or its appropriate parametabic salt , And methods for preparing them

Country Status (29)

Country Link
US (1) US20110014283A1 (enExample)
EP (1) EP2131818B1 (enExample)
JP (2) JP5743177B2 (enExample)
KR (1) KR101504371B1 (enExample)
CN (1) CN101674806B (enExample)
AR (1) AR065529A1 (enExample)
AU (1) AU2008220795B2 (enExample)
BR (1) BRPI0807882A2 (enExample)
CA (1) CA2679529A1 (enExample)
CL (1) CL2008000596A1 (enExample)
CO (1) CO6220900A2 (enExample)
CR (1) CR11013A (enExample)
DK (1) DK2131818T3 (enExample)
DO (1) DOP2009000207A (enExample)
EA (1) EA019865B1 (enExample)
ES (1) ES2463468T3 (enExample)
HR (1) HRP20140390T1 (enExample)
IL (1) IL200619A (enExample)
MA (1) MA31198B1 (enExample)
MX (1) MX2009009362A (enExample)
NZ (1) NZ579374A (enExample)
PE (1) PE20090114A1 (enExample)
PL (1) PL2131818T3 (enExample)
PT (1) PT2131818E (enExample)
SI (1) SI2131818T1 (enExample)
TW (1) TWI424856B (enExample)
UA (1) UA102515C2 (enExample)
WO (1) WO2008104590A2 (enExample)
ZA (1) ZA200905866B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
EP2328587A1 (en) * 2008-08-29 2011-06-08 Glaxo Group Limited Dosage form comprising 1-isopropyl-4-{ [4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine or a salt thereof
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
AU2016274694A1 (en) 2015-06-10 2018-01-18 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7719894A (en) * 1993-09-03 1995-03-22 Smithkline Beecham Corporation Stabilized tablet formulation
IL143299A0 (en) * 1998-12-01 2002-04-21 Novo Nordisk As Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
MXPA05006567A (es) * 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
CA2529320C (en) * 2003-06-17 2013-03-05 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
US20070021391A1 (en) * 2003-06-30 2007-01-25 Takayuki Doi Preventive/remedy for urinary disturbance
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
JP2008502644A (ja) * 2004-06-18 2008-01-31 グラクソ　グループ　リミテッド ヒスタミンｈ３アンタゴニストとしての３−シクロアルキルベンズアゼピン
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CL2008000596A1 (es) 2008-09-05
HRP20140390T1 (hr) 2014-06-06
CA2679529A1 (en) 2008-09-04
DK2131818T3 (da) 2014-05-26
NZ579374A (en) 2012-01-12
AU2008220795A1 (en) 2008-09-04
CN101674806A (zh) 2010-03-17
US20110014283A1 (en) 2011-01-20
EP2131818A2 (en) 2009-12-16
ZA200905866B (en) 2010-05-26
EA200970817A1 (ru) 2010-06-30
CN101674806B (zh) 2013-03-13
IL200619A0 (en) 2010-05-17
PT2131818E (pt) 2014-06-05
KR101504371B1 (ko) 2015-03-19
MX2009009362A (es) 2009-09-14
AR065529A1 (es) 2009-06-10
CR11013A (es) 2009-12-15
ES2463468T3 (es) 2014-05-28
PL2131818T3 (pl) 2014-08-29
HK1137363A1 (en) 2010-07-30
BRPI0807882A2 (pt) 2014-06-17
EA019865B1 (ru) 2014-06-30
SI2131818T1 (sl) 2014-06-30
JP2015038098A (ja) 2015-02-26
EP2131818B1 (en) 2014-04-09
PE20090114A1 (es) 2009-04-13
JP2010520174A (ja) 2010-06-10
CO6220900A2 (es) 2010-11-19
TWI424856B (zh) 2014-02-01
JP5743177B2 (ja) 2015-07-01
AU2008220795B2 (en) 2013-06-06
KR20090127311A (ko) 2009-12-10
TW200900093A (en) 2009-01-01
UA102515C2 (ru) 2013-07-25
DOP2009000207A (es) 2009-10-31
MA31198B1 (fr) 2010-02-01
WO2008104590A2 (en) 2008-09-04
WO2008104590A3 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
AU2008220795B2 (en) Novel dosage form
KR101290925B1 (ko) 코팅된 정제 제형 및 방법
CN101711752B (zh) 一种苯并异噁唑类衍生物的控释制剂及其制备方法
CA3207049A1 (en) Irak4 degraders and uses thereof
US20110020447A1 (en) Novel dosage form
KR20190059868A (ko) 바레니클린 살리실레이트를 함유하는 서방성 제제 및 이의 제조 방법
WO2008125843A9 (en) Pharmaceutical compositions
CN116159033B (zh) 一种氨氯地平贝那普利固体制剂及其制备工艺
US20110189280A1 (en) Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof
HK1137363B (en) Novel dosage form

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees